English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Pulmonary Fibrosis Foundation has named Cedars-Sinai part of its Care Center Network, a group of medical centers that have demonstrated expertise in treating and supporting people with this deadly disease.
Tag: Idiopathic Pulmonary Fibrosis
Researchers ID Role of Enzyme as Regulator of Inflammation in Lung Disease
Article title: Pim-1 kinase is a positive feedback regulator of the senescent lung fibroblast inflammatory secretome Authors: Ashley Y. Gao, Ana M. Diaz Espinosa, Fiorenza Gianì, Tho X. Pham, Chase M. Carver, Aja Aravamudhan, Colleen M. Bartman, Giovanni Ligresti, Nunzia…
HER2 Pathways in Breast Cancer May Hold Key to Effective Treatment of Idiopathic Pulmonary Fibrosis
LOS ANGELES (Oct. 13, 2022) — FINDINGS A new study led by Cedars-Sinai investigators suggests HER2 signaling may be a key driver of fibroblast invasion and can serve as a target for therapeutic intervention in idiopathic pulmonary fibrosis. HER2 is…
Post-COVID Lung Disease Shares Origins with Other Scarring Lung Disorders
UC San Diego researchers provide first insights into the fundamental cellular pathologies that drive interstitial lung disease in patients post-COVID.
New Clinical Practice Guidelines on Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Almost four years since the last guidance on the diagnosis and management of idiopathic pulmonary fibrosis, the American Thoracic Society – in collaboration with the European Respiratory Society, Japanese Respiratory Society and Asociacion Latinoamericana de Torax – has issued new guidelines for clinicians. The guidelines are available online in the May 1 issue of the American Journal of Respiratory and Critical Care Medicine.
The Role of Air Pollution in Pulmonary Fibrosis
To mark Clean Air Month, the Pulmonary Fibrosis Foundation (PFF) aims to increase public understanding of the role air pollution has in the development of interstitial lung diseases (ILD) such as pulmonary fibrosis (PF), including how polluted air can make you sick and the telltale signs to be aware of.
Targeting mechanosensitive protein could treat pulmonary fibrosis, study suggests
Researchers at the University of Alabama at Birmingham have identified a new molecular target that could potentially treat the deadly, aging-related lung disease idiopathic pulmonary fibrosis (IPF). The study, which will be published March 10 in the Journal of Experimental Medicine (JEM), suggests that targeting a protein called MDM4 could prevent respiratory failure by initiating a genetic program that removes scar tissue from the lungs.
Learn the Symptoms of Pulmonary Fibrosis this Rare Disease Day
To mark Rare Disease Day on February 28, the Pulmonary Fibrosis Foundation (PFF) aims to increase public understanding of pulmonary fibrosis (PF) to drive home the importance of early diagnosis to help improve the quality of life for patients.
Pulmonary Fibrosis Foundation Announces Sponsorship by United Therapeutics
The Pulmonary Fibrosis Foundation (PFF) has announced United Therapeutics’ sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with pulmonary fibrosis nationwide.
Pulmonary Fibrosis Foundation Launches Campaign To Raise PF Awareness And Early Diagnosis
The Pulmonary Fibrosis Foundation today announced the “Pinpoint PF” education and awareness campaign aimed at individuals with symptoms and at a higher risk for pulmonary fibrosis (PF).
Healthy Lung Month: Know these pulmonary fibrosis risk factors
October is Healthy Lung Month, an apt time to educate the public about the importance of protecting our lungs against mold, airborne pollutants and smoking – which put hundreds of thousands of Americans at higher risk for pulmonary fibrosis (PF).
Pulmonary Fibrosis Awareness Month Highlights Realities of Rare Disease
September’s Pulmonary Fibrosis Awareness Month shares crucial realities and insights about the rare disease, its symptoms and helpful resources provided by the Pulmonary Fibrosis Foundation to educate the public about this devastating disease which impacts over 200,000 Americans.